Frovatriptan contraindications

Revision as of 22:26, 9 February 2014 by Gerald Chi (talk | contribs)
Jump to navigation Jump to search
Frovatriptan
FROVA® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Frovatriptan
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Contraindications

FROVA is contraindicated in patients with:

  • Ischemic coronary artery disease (CAD) (e.g. angina pectoris, history of myocardial infarction, or documented silent ischemia), or coronary artery vasospasm, including Prinzmetal’sangina [see Warnings and Precautions (5.1)].
  • Wolff-Parkinson-White Syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions (5.2)].
  • History of stroke, transient ischemic attack (TIA), or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [see Warnings and Precautions (5.4)].
  • Peripheral vascular disease [see Warnings and Precautions (5.5)].
  • Ischemic bowel disease [see Warnings and Precautions (5.5)].
  • Uncontrolled hypertension [see Warnings and Precautions (5.8)].
  • Hypersensitivity to FROVA (angioedema and anaphylaxis seen) [see Warnings and Precautions (5.9)].[1]

References

  1. "FROVA (FROVATRIPTAN SUCCINATE) TABLET, FILM COATED [ENDO PHARMACEUTICALS INC.]". Retrieved 7 February 2014.

Template:WikiDoc Sources